Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Instagram Outage Disrupts Thousands of U.S. Users 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SAN DIEGO, Aug. 29, 2017 -- Oxeia Biopharmaceuticals, Inc. has been invited to present at the 2017 Gateway Conference, which is being held on September 6-7, 2017 at the Four Seasons Hotel San Francisco.
Oxeia management is scheduled to present on Wednesday, September 6 at 2:00 pm Pacific Time, with one-on-one meetings held throughout the conference. The presentation will be webcast live and available for replay in the Investor Relations section of Oxeia’s website at www.oxeiabiopharma.com or on the Gateway Conference website at www.gateway-conference.com/presenters. To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected].
About the Gateway Conference
The 6th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.
About Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc. is a privately held clinical stage biotechnology company headquartered in San Diego, CA. The company is focused on developing treatments for concussions and other acute neurotrauma conditions. Oxeia’s lead program, OXE-103, uniquely targets the metabolic dysfunction and subsequent neurotrauma underlying acute concussion pathophysiology. Oxeia anticipates initiating Phase 2 studies for OXE-103 in concussion and additional neurological indications in early 2018. The program has maintained a strong safety profile across nine previous clinical studies totaling 345 patients.
Contact: Kartik Shah Chief Business Officer Oxeia Biopharmaceuticals, Inc [email protected] 207.232.2863 Marek Ciszewski, J.D. Liolios, Inc. [email protected] 949.574.3860
